Skip to main content

Table 2 Overall survival of the whole cohort at 3 years by surgical specimen (after chemotherapy) immune biomarker expression and overall survival for the subgroup of patients that failed to achieve pCR (no-pCR group)

From: Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study

  Evt/N 3yr-OS 95% CI  
All patients
 PD-L1     p = 0.0055
  Negative (IC0) 4/38 89.4% 70.6–96.5
  Positive (IC1/2/3) 9/28 57.4% 33.2–75.5
 TILs     p = 0.6312
  0–10% 6/35 79.6% 57.0–91.2
  > 10% 7/31 72.5% 50.6–85.9
 TIM-3     p = 0.0840
  < 1% 2/21 93.8% 63.2–99.1
  ≥ 1% 11/45 67.0% 48.0–80.5
 TIM-3     p = 0.0274
  0–4% 5/44 87.1% 68.6–95.1
  ≥ 5% 8/22 58.0% 33.1–76.4
 LAG-3     p = 0.7750
  0 2/11 88.9% 43.3–98.4
  > 0 11/55 73.5% 56.9–84.5
 PD-L1 and TIM-3     p = 0.0020
  Others 7/54 84.6% 68.5–92.9
  PD-L1+/TIM-3+ 6/12 45.5% 16.7–70.7
No-pCR group
 PD-L1     p = 0.1186
  Negative (IC0) 3/14 84.6% 51.2–95.9
  Positive (IC1/2/3) 8/23 58.0% 33.0–76.5
 TILs     p = 0.8008
  0–10% 5/16 72.0% 41.1–88.6
  > 10% 6/21 65.7% 38.8–83.0
 TIM-3     p = 0.0702
  0–4% 3/20 88.7% 61.4–97.1
  ≥ 5% 8/17 50.0% 24.5–71.0
 PD-L1 and TIM-3     p = 0.0479
  Others 5/25 81.3% 57.3–92.6
  PD-L1+/TIM-3+ 6/12 45.5% 16.7–70.7